| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Yvonne L. Greenstreet
Also a director
Chief Executive Officer
|
63 |
Since 2022
4 years
|
Not stated | $14,867,600 | |
|
Jeffrey V. Poulton
Executive Vice President and Chief Financial Officer
|
58 |
Since 2019
7 years
|
Not stated | $6,863,800 | |
|
Pushkal Garg
Executive Vice President and Chief Research and Development Officer
|
58 |
Since 2025
1 year
|
2014 | $6,490,500 | |
|
Bryan A. Supran
Executive Vice President, Chief Legal Officer and Secretary
|
55 |
Since 2025
1 year
|
Not stated | $6,846,350 | |
|
Kevin J. Fitzgerald
Executive Vice President, Chief Scientific Officer and Head of Early Research and Early Development
|
58 |
Since 2023
3 years
|
2005 | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 6, 2026 · updated by the 8-K of May 27, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Amy W. Schulman
Board chair
|
65 |
2014
12 years
|
Not stated |
People, Culture and Compensation Committee
Nominating and Corporate Governance Committee
|
Elevance Health | $541,310 | |
|
Yvonne L. Greenstreet, M.D.
CEO
|
63 |
2021
5 years
|
Not independent | None stated | None stated | Paid as CEO | |
|
Elliott Sigal, M.D., Ph.D.
|
74 |
2022
4 years
|
Independent |
People, Culture and Compensation Committee
Science and Technology Committee · Chair
|
Vir Biotechnology, Inc. | $486,310 | |
|
Dennis A. Ausiello, M.D.
|
80 |
2012
14 years
|
Independent |
Nominating and Corporate Governance Committee
Science and Technology Committee
|
Seres Therapeutics, Inc., Rani Therapeutics Holdings, Inc. | $479,850 | |
|
Olivier Brandicourt, M.D.
|
70 |
2020
6 years
|
Independent |
People, Culture and Compensation Committee
Audit Committee
|
BeOne Medicines Ltd., Vaxcyte, Inc. | $482,350 | |
|
Peter N. Kellogg
|
69 |
2023
3 years
|
Independent |
Audit Committee · Chair
|
None stated | $484,850 | |
|
David E.I. Pyott
|
72 |
2015
11 years
|
Independent |
Nominating and Corporate Governance Committee · Chair
|
Pliant Therapeutics, Inc., Tarsus Pharmaceuticals | $479,850 | |
|
Margaret A. Hamburg, M.D.
|
70 |
2019
7 years
|
Independent |
Nominating and Corporate Governance Committee
|
None stated | $469,850 | |
|
Colleen F. Reitan
|
66 |
2018
8 years
|
Independent |
Audit Committee
People, Culture and Compensation Committee · Chair
|
Myriad Genetics, Inc. | $492,350 | |
|
Benjamin F. Cravatt
Joined Jun 1, 2026
|
- | - | - |
Science and Technology Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 6, 2026 states there were none.
Read it in the proxyLoading...